relatlimab,nivolumab
bms
['nivo', 'neopredict', 'nivolumab', 'relatlimab', 'nsclc', 'sclc']
the primary end point of feasibility was met in the phase 2 neopredict trial with preoperative nivolumab plus or minus relatlimab when administered to patients with resectable nsclc. #esmo2022 | 
Oncology news and insights from leading researchers and cancer centers.